Morningside Venture Investments Ltd - 06 Jan 2022 Form 4/A - Amendment Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
10%+ Owner
Signature
/s/ Frances Anne Elizabeth Richard, for Morningside Venture Investments Limited
Issuer symbol
AMLX
Transactions as of
06 Jan 2022
Net transactions value
+$5,000,002
Form type
4/A - Amendment
Filing time
17 Mar 2022, 17:14:49 UTC
Date Of Original Report
25 Jan 2022
Previous filing
18 Nov 2021
Next filing
17 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Conversion of derivative security +10,415,650 10,415,650 11 Jan 2022 See Footnotes F1, F2, F3
transaction AMLX Common Stock Purchase $5,000,002 +263,158 +2.5% $19.00 10,678,808 11 Jan 2022 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Series A Preferred Stock Conversion of derivative security $0 -1,409,035 -100% $0.000000* 0 11 Jan 2022 Common Stock 1,409,035 See Footnote F1, F2
transaction AMLX Series B Preferred Stock Conversion of derivative security $0 -6,410,964 -100% $0.000000* 0 11 Jan 2022 Common Stock 6,410,964 See Footnote F1, F2
transaction AMLX Series C-1 Preferred Stock Conversion of derivative security $0 -974,107 -100% $0.000000* 0 11 Jan 2022 Common Stock 974,107 See Footnote F1, F2
transaction AMLX Series C-2 Preferred Stock Conversion of derivative security $0 -1,621,544 -100% $0.000000* 0 11 Jan 2022 Common Stock 1,621,544 See Footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.
F2 Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, are the directors of Morningside Venture Investments Limited ("Morningside") and share voting and dispositive power with respect to the securities held by Morningside and MVIL, LLC ("MVIL LLC"), Morningside's wholly-owned subsidiary. Cheng Yee Wing Betty and Wong See Wai are the managers of MVIL LLC and share voting and dispositive power with respect to the securities held by MVIL LLC. Ms. Cheng and Mr. Wong each disclaim ownership of the securities owned by MVIL LLC.
F3 The shares of Series C-2 Preferred Stock and the Common Stock received upon conversion of the C-2 Preferred Stock are held by MVIL LLC.

Remarks:

The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.